TCH GROUP, LLC for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
S. 1298, F.Y. 2010 Homeland Security Appropriations, drug importation issues. Monitored appropriation process; S. 1406, F.Y. 2010 Agriculture Appropriations, FDA funding, importation, Monitored appropriation process; H.R. 2847, F.Y. 2010 Commerce, Justice, Science Appropriations, importation issues. Monitored appropriations process.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Copyright/Patent/Trademark CPT
H.R. 1260, Patent Reform Act of 2009: patent reform issues; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements; S. 369, Preserve Access to Affordable Generics Act: patent settlements; S. 515, Patent Reform Act of 2009: patent reform issues; S. 610, Patent Reform Act of 2009: patent reform issues; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Health Issues HCR
S.- America's Healthy Future Act. (Finance Committee Version); S. 1679- The Affordable Health Choices Act; H.R. 3200: America's Affordable Health Choices Act of 2009; H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics; H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness; S. 488, Access to Cancer Clinical Trials Act of 2009, access to clinical trials; S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; S. 1142, Informed Health Care Decision Making Act: drug labeling; S. 1213, Patient-Centered Outcomes and Research Act of 2009: comparative effectiveness; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 1679, Affordable Health Choices Act: health reform, regulatory pathway for follow-on biologics, 340B program issues; H.R. 759, Food and Drug Administration Globalization Act, 2009: import safety; S. 623, Access to Life-Saving Medicine Act; Follow-on biologics
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Medicare/Medicaid MMM
S. 301, Physician Payments Sunshine Act of 2009: transparency issues; S. 330, Medicare Prescription Drug Savings and Choice Act: Part D issues; S. 458, False Claims Act Clarification Act of 2009: liability issues; S. 1110, Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009: Medicare payment issues; Health care reform issues, Senate Finance Committee options papers; H.R. 1788, False Claims Act of 2009; H.R. 684, Medicare Prescription Drug Cost Equalization Act, Part D issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.